Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1801 • ACR Convergence 2021
The Effect of Ixekizumab versus Adalimumab on Individual Components of the ACR Composite Score, with and Without Concomitant Methotrexate or Other Conventional Synthetic DMARDs at 52 Weeks in Patients with Psoriatic Arthritis
Elaine Husni¹, Sona Kamat², Keri Stenger³, Rebecca Bolce³, Thorsten Holzkaemper⁴, Cameron Helt³, So Young Park³, Jeffrey Lisse⁵ and Luca Idolazzi⁶, ¹Cleveland Clinic, Cleveland, OH, ²St Louis University, Saint Louis, MO, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Bad Homburg, Germany, ⁵Eli Lilly and Company, Tucson, AZ, ⁶University of Verona, Verona, Italy
Background/Purpose: It is important to understand how to select among the multiple treatment options for active psoriatic arthritis (PsA). Since individual patient domains may influence…
Abstract Number: 1819 • ACR Convergence 2021
Tildrakizumab Efficacy and Safety in Patients with Psoriatic Arthritis by Metabolic Syndrome Status
Arthur Kavanaugh¹, Siba Raychaudhuri², Christopher Ritchlin³, Akihiko Asahina⁴, Proton Rahman⁵, Fred Murphy⁶, Stephen Rozzo⁷, Siu-Long Yao⁷, Richard C Chou⁸ and Elaine Husni⁹, ¹Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, ²Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, Sacramento, CA, ³Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁴Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ⁵Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁸University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, Buffalo, NY, ⁹Cleveland Clinic, Cleveland, OH
Background/Purpose: Metabolic syndrome (MetS) is a combination of specific risk factors for cardiovascular disease.1 The prevalence of MetS in patients (pts) with PsA has been…
Abstract Number: 1921 • ACR Convergence 2021
Axial Psoriatic Arthritis: Correlation Between Whole Spine MRI Abnormalities and Clinical Findings
Pamela Diaz¹, Iris Eshed², Joy Feld³ and Lihi Eder¹, ¹University of Toronto, Toronto, ON, Canada, ²Sheba Medical Center, Ramat Gan, Israel, ³Carmel and Zvulun Medical Centre, Haifa, Israel
Background/Purpose: Psoriatic Arthritis (PsA) typically affects peripheral joints, but in some patients the disease can involve the spine. While magnetic resonance imaging (MRI) is an…
Abstract Number: 0061 • ACR Convergence 2021
Harnessing Spatially-Resolved Gene Expression to Characterize the Transcriptional Landscape of Psoriatic Skin
Rochelle Castillo¹, Ikjot Sidhu¹, Di Yan¹, Piotr Konieczny¹, Rebecca Haberman¹, Brandon Hsieh¹, Andrea Neimann¹, Shruti Naik¹ and Jose Scher², ¹NYU Langone Health, New York, NY, ²New York University School of Medicine, New York, NY
Background/Purpose: The skin is recognized as a window into the immunopathogenic mechanisms in the psoriatic arthritis (PsA) joint. This is evidenced by the fact that…
Abstract Number: 0452 • ACR Convergence 2021
Total-Body 18F-FDG PET/CT Imaging: A Tool for Diagnosis and Quantifying Inflammatory Burden of Psoriatic Arthritis
Siba Raychaudhuri¹, Yasser Abdelhafez², Smriti Kundu-Raychaudhuri² and Abhijit Chaudhari², ¹Sacramento Veterans Affairs Medical Center (VAMC)/University of California-Davis Health, Davis, CA, ²UC Davis School of Medicine, Davis, CA
Background/Purpose: The underlying pathology in psoriatic arthritis (PsA) is systemic inflammation. The Total Body (TB)-PET/CT with the 18F-FDG radiotracer captures glucose metabolism across the entire…
Abstract Number: 0817 • ACR Convergence 2021
Biosimilar Infliximab Therapy in Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis: A Long-term Follow-up Study on Infliximab-naive Patients and Switched Patients from the Originator to the Biosimilar CT-P13
Hubert MAROTTE¹, Maryse Assing², Nadir Mammar², Yves Brault³ and Bruno Fautrel⁴, ¹Rheumatology department - Unisersity Hospital of Saint-Etienne, Saint-Etienne, France, ²Inflammation & Immunology - Pfizer, Paris, France, ³Pfizer, Paris, France, ⁴Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France
Background/Purpose: ReFLECT study has been carried out to investigate real life use of CT-P13, the first monoclonal antibody biosimilar to infliximab (IFX) originator.Methods: ReFLECT is…
Abstract Number: 1304 • ACR Convergence 2021
Increased Risk of Vertebral Fracture Among Patients with Psoriatic Arthritis: A Systematic Review and Meta-analysis
Patompong Ungprasert¹, Nipith Charoenngam², Ben Ponvilawan³, Jerapas Thongpiya⁴ and Pitchaporn Yingchoncharoen³, ¹Cleveland Clinic, Cleveland Heights, OH, ²Mount Auburn Hospital, Boston, MA, ³Mahidol University, Bangkok, Thailand, ⁴Mahdiol University, Bangkok, Thailand
Background/Purpose: Increased risk of vertebral fracture (VF) has been documented in several autoimmune diseases as a result of excessive inflammatory burden and use of corticosteroids.…
Abstract Number: 1334 • ACR Convergence 2021
How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Jrgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Universitätsklinikum Würzburg, Wuerzburg, Germany
Background/Purpose: Gender disparities in PsA can affect natural course of disease, clinical presentation and response to medication1. The German non-interventional study AQUILA provides real-world data…
Abstract Number: 1351 • ACR Convergence 2021
The Impact of Skin Involvement and Depression on Patient Acceptable Symptom State in Patients with Psoriatic Arthritis and Psoriasis: Results from a Multinational Survey
Alexis Ogdie-Beatty¹, Joseph Merola², Pascal Richette³, Sven Richter⁴, Shauna Jardon⁵, Lihua Tang⁴ and William Tillett⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ³Lariboisiere Hospital, Paris, France, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Amgen Inc., Gilbert, AZ, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Depression, a common comorbidity in patients with psoriasis (PsO) and PsA, has been shown to be independently associated with Psoriatic Arthritis Impact of Disease…
Abstract Number: 1691 • ACR Convergence 2021
Long-Term Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
Gerd Burmester¹, Stanley Cohen², Kevin Winthrop³, Peter Nash⁴, Andrea Rubbert-Roth⁵, Atul Deodhar³, Ori Elkayam⁶, Eduardo Mysler⁷, Yoshiya Tanaka⁸, Jianzhong Liu⁹, Ana Paula Lacerda⁹, Bosny Pierre-Louis⁹, Tim Shaw¹⁰ and Philip Mease¹¹, ¹Charité University Medicine Berlin, Berlin, Germany, ²Metroplex Clinical Research Center, Dallas, TX, ³Oregon Health & Science University, Portland, OR, ⁴Griffith University, Brisbane, Australia, ⁵Kantonspital St Gallen, St.Gallen, Switzerland, ⁶Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷Organización Medica de Investigación, Rheumatology, Buenos Aires, Argentina, ⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹AbbVie Inc., North Chicago, IL, ¹⁰AbbVie Inc., North Chicago, ¹¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: The efficacy and safety of the oral Janus kinase inhibitor, upadacitinib (UPA), has been evaluated for several rheumatic diseases. The objective of this analysis…
Abstract Number: 1786 • ACR Convergence 2021
Association of the Improvement of Synovitis and Enthesitis with Quality of Life/Patient Reported Outcomes in Patients with PsA Treated with Ixekizumab
Lars Erik Kristensen¹, Dennis McGonagle², Martin Rudwaleit³, Hideto Kameda⁴, Thorsten Holzkaemper⁵, Celine El Baou⁶ and Josef Smolen⁷, ¹Bispebjerg-Frederiksberg Hospital, Copenhagen,, Denmark, ²University of Leeds, Leeds, United Kingdom, ³Bielefeld University, Rheumatology, Klinikum Bielefeld, Berlin, Germany, ⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵Eli Lilly and Company, Bad Homburg, Germany, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Medical University of Vienna, Vienna, Austria
Background/Purpose: PsA is an inflammatory rheumatic disease with manifestations including synovitis and enthesitis. During extensive study programs, IXE has shown a treatment effect across domains…
Abstract Number: 1803 • ACR Convergence 2021
Long-term Safety of Guselkumab (TREMFYA®) in Patients with Active Psoriatic Arthritis: Pooled Results from 3 Randomized Clinical Trials Through up to 2 Years
Proton Rahman¹, Christopher Ritchlin², Philip Mease³, Philip S Helliwell⁴, Wolf-Henning Boehncke⁵, Iain McInnes⁶, May Shawi⁷, Anne Marilise Marrache⁸, Alexa Kollmeier⁹, Xie Xu¹⁰, Jenny Yu¹⁰, Yanli Wang¹⁰, Shihong Sheng¹⁰ and Alice Gottlieb¹¹, ¹Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ²Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Geneva University Hospitals, Geneva, Switzerland, ⁶University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Janssen Inc., Toronto, ON, Canada, ⁹Janssen Research & Development, LLC, La Jolla, CA, ¹⁰Janssen Research & Development, LLC, Spring House, PA, ¹¹Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Guselkumab (GUS), a targeted IL-23 inhibitor, demonstrated significant improvements in signs and symptoms of psoriatic arthritis (PsA) and a favorable safety profile through week…
Abstract Number: 1820 • ACR Convergence 2021
Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Musculoskeletal Manifestations of Active PsA in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Philip Mease¹, Atul Deodhar², Désirée van der Heijde³, Frank Behrens⁴, Alan Kivitz⁵, Tom Lehman⁶, Lan Wei⁶, Marleen Nys⁷, Subhashis Banerjee⁶ and Miroslawa Nowak⁶, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁴CIRI/Rheumatology and Fraunhofer Institute, Translational Medicine and Pharmacology ITMP, Goethe University, Frankfurt, Germany, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Braine-l'Alleud, Belgium
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates IL-23, IL-12, and IFNα/β signaling. Deucravacitinib is a novel, oral selective inhibitor of TYK2…
Abstract Number: 1925 • ACR Convergence 2021
Risk of Heart Failure in Patients with Inflammatory Disease: A Population-Based Study
Sahil Koppikar¹, Bindee Kuriya², Jacob Udell³, Bing Yu⁴, Anna Chu⁴, Laura Ferreira-Legere⁵, Douglas Lee³, Jessica Widdifield⁶ and Lihi Eder³, ¹Women's College Hospital, Toronto, ON, Canada, ²University of Toronto - Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴ICES, Toronto, ON, Canada, ⁵ICES, Toronto, Canada, ⁶Sunnybrook Research Institute; ICES; Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Individuals with inflammatory diseases (ID) have an increased risk of cardiovascular disease, frequently compared to that of diabetes mellitus (DM). However, the magnitude of…
Abstract Number: 0063 • ACR Convergence 2021
Development of a Novel Cartilage Model Co-cultured with Conditioned Medium from Th17 Cells to Explore the Effect of IL-17A on Joint Tissue Remodeling
Solveig S. Groen¹, Christian S Thudium², Morten Karsdal³, Anne-Christine Bay-Jensen² and Signe Holm Nielsen⁴, ¹University of Copenhagen, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Nordic Bioscience, Herlev, ⁴Nordic Bioscience and Technical University of Denmark, Biomedicine and Biotechnology, Kgs. Lyngby, Herlev, Denmark
Background/Purpose: In spondyloarthritis (SpA) Th17 cells play a critical role in activating the pathogenic chain leading to manifestations related to skin, joints and entheses. Elevated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].